Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- President Trump announced 100% tariffs on all imported branded and patent-protected medicines to the US starting October 1, 2025, unless companies are actively building manufacturing plants in America. - Indian pharmaceutical stocks plummeted up to 5% following the announcement, with Sun Pharma hitting its yearly low and the Nifty Pharma Index declining 2.54%. - The policy could significantly impact Indian pharma companies that generate substantial revenue from US exports, potentially affecting over $233 billion of US pharma imports while exempting generic drug exporters. - Companies may face reduced profits or be forced to invest in expensive US manufacturing facilities to avoid the tariffs and maintain market access.
- Indian Contract Research and Development and Manufacturing Organizations (CRDMOs) are attracting increased attention from global pharmaceutical companies as Big Pharma pursues geographic diversification strategies. - Rising demand for antibody-drug conjugate (ADC)-related CDMO services and future opportunities in GLP-1 diabetes and obesity treatments are positioned as significant growth drivers from 2026. - Key players including Piramal Pharma, Syngene, Laurus Labs, Cohance, and Gland Pharma are strategically positioning for future gains despite current destocking challenges affecting near-term growth. - Gland Pharma is expanding its GLP-1 cartridge fill-finish capacity from 40 million to 140 million units by the end of next year, reflecting the industry's optimistic long-term outlook.
- Gland Pharma has received USFDA approval for Acetaminophen Injection (10 mg/mL) in 500mg/50mL and 1000mg/100mL bag formulations for pain management. - The injectable product is indicated for mild to moderate pain management in patients 2 years and older, and for moderate to severe pain when used with opioid analgesics. - With US sales of approximately $55 million for the twelve months ending February 2025, Gland Pharma plans to launch the product through a marketing partner soon.
- Gland Pharma has secured US FDA approval for its phytonadione injectable emulsion, a generic version of vitamin K1 injectable emulsion. - The drug is indicated for treating coagulation disorders resulting from vitamin K deficiency or interference with vitamin K activity. - The company plans to launch the product through its marketing partners, with US sales for the reference drug estimated at $15 million annually. - Gland Pharma's stock experienced a rally following the announcement, reflecting positive market sentiment.
- Gland Pharma has received US FDA approval for Latanoprost Ophthalmic Solution, 0.005% (2.5 mL Fill), a generic equivalent to Xalatan. - The ophthalmic solution is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. - Gland Pharma plans to launch the product through its marketing partners in FY25, targeting a market with approximately $111.6 million in US sales. - This approval strengthens Gland Pharma's position in the US pharmaceutical market, expanding its portfolio of sterile injectable and ophthalmic solutions.
